Lab
BCW Puerto Rico, LLC
BCW Puerto Rico, LLC was paid $381K by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 14% of everything it billed.
33Billing provider infoBCW PUERTO RICO, LLC
CATANO, PR 00962
CATANO, PR 00962
33aNPI1528124476assigned 12/28/2006
33bProvider typeClinical Medical Laboratory
28Total paid$381K
24GClaims27,941
24DCodes billed35
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#318 of 777
Median peer was paid$278K
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,220 | $22K | |
| 2019 | 1,946 | $15K | |
| 2020 | 1,991 | $21K | |
| 2021 | 2,896 | $34K | |
| 2022 | 7,235 | $140K | |
| 2023 | 6,600 | $83K | |
| 2024incomplete | 5,053 | $66K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 14% | 1,143 | 1,018 | $53K |
| 84443 | Thyroid stimulating hormone (TSH) | 12% | 2,984 | 2,813 | $47K |
| 80061 | Lipid panel | 9.9% | 2,937 | 2,771 | $38K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 9.8% | 1,699 | 1,534 | $37K |
| 80053 | Comprehensive metabolic panel | 9.1% | 3,425 | 3,195 | $35K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8.4% | 4,266 | 3,958 | $32K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.0% | 749 | 705 | $30K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.2% | 573 | 522 | $16K |
| 80074 | 3.5% | 318 | 284 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.5% | 1,450 | 1,369 | $13K |
| 81000 | 2.8% | 3,456 | 3,246 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.5% | 253 | 230 | $9K |
23 more codes
| 86701 | 2.2% | 977 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.9% | 588 | $7K |
| 82274 | 1.6% | 412 | $6K | |
| 84439 | 1.5% | 652 | $6K | |
| 86738 | 1.5% | 358 | $6K | |
| 87590 | <1% | 166 | $3K | |
| 82043 | <1% | 407 | $2K | |
| 87400 | <1% | 191 | $2K | |
| 87088 | <1% | 216 | $2K | |
| 86592 | <1% | 301 | $1K | |
| 84436 | <1% | 93 | $598.79 | |
| 84153 | <1% | 36 | $278.19 | |
| 87275 | <1% | 23 | $272.78 | |
| 87276 | <1% | 23 | $272.78 | |
| 82570 | <1% | 41 | $215.34 | |
| 84479 | <1% | 29 | $202.41 | |
| 85651 | <1% | 68 | $194.89 | |
| 86696 | <1% | 19 | $189.90 | |
| 86694 | <1% | 19 | $141.21 | |
| 86695 | <1% | 19 | $129.42 | |
| 86790 | <1% | 19 | $126.36 | |
| 82378 | <1% | 18 | $124.02 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPACHECO, SIXTO (PRESIDENT & CEO)